Table 1. Characteristic studies of meta-analysis.

Study	Sample size	Male ratio %	Mean age, y	CKD stage	Usage of iron	Use of EPO	Company	Dosage of roxadustat	Duration of treatment
Besarab 2015	88 subjects/28 controls	42.2	65.8 [47–82]	3 to 4	Oral only	No	FibroGen	0.7 g, 1.0, 1.5 and 2.0 mg/kg at BIW or TIW	29 days for BIW and 26 days for TIW
Chen 2017	61 subjects/30 controls	28.6	49.7±13.2	1 to 4	Oral only	No	FibroGen	low- (1.1–1.75 mg/kg) and high-dose (1.50–2.25mg/kg) TIW	8 weeks
Akizawa 2019	80 subjects/27 controls	46.7	63.8±9.2	2 to 5	Oral was allowed and intravenous iron was used if TSAT <5% and ferritin <30 ng/mL	No	Astellas	50, 70 and 100 mg TIW in fixed-dose period, and adjusted dose in titration period	6 weeks fixed-dose period and 18 weeks titration period

TIW, three times weekly; BIW, two time weekly; EPO, erythropoietin; TAST, transferrin saturation.